ArticleJournal of dental sciences2025
3,4-methylenedioxymethamphetamine induces reactive oxygen species-mediated autophagy and thioredoxin-interactive protein/nucleotide-binding domain, leucine-rich containing family, pyrin domain-containing-3 inflammasome activation in dental pulp stem cells.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: 3,4-methylenedioxymethamphetamine (MDMA) is a synthetic substituted amphetamine. Research primarily focuses on its neurotoxicity and psychological effects, while studies examining its impact on mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) are relatively limited. This study investigated the cytotoxicity and molecular mechanisms of MDMA in DPSCs. Materials and methods: Cell viability, apoptosis, autophagy, immunophenotype, reactive oxygen species (ROS), and the related signaling pathways were analyzed using a cell counting kit, Western blot, flow cytometry, and 2',7'-dichlorofluorescein diacetate (DCFH-DA) dye after treating DPSCs with indicated concentrations of MDMA. Results: MDMA significantly decreased cell viability and increased cleaved poly adenosine diphosphate-ribose polymerase (PARP), cleaved caspase-8, cleaved caspase-3, and Bcl-2-associated X protein (Bax), while reducing B-cell lymphoma 2 (Bcl-2). Annexin V and 7-aminoactinomycin D (7-AAD) flow cytometry showed that these cells underwent early apoptosis without altering MSCs' immunophenotypic properties. MDMA also induced ROS accumulation and nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation. Autophagy activation was observed with adenosine monophosphate-activated protein kinase (AMPK) activation, protein kinase B (AKT) inactivation, and mammalian target of rapamycin (mTOR) suppression. Autophagy inhibitor chloroquine (CQ) attenuated MDMA-induced cell death, suggesting that excessive autophagy contributes to cell damage. Conclusion: MDMA induces ROS-mediated autophagic cell death and thioredoxin-interacting protein (TXNIP)/NLRP3 inflammasome activation, causing detrimental cell damage. The historical roots of drug addiction should be considered when modifying dental approaches for patients with a history of MDMA use, as well as in the screening of DPSCs donors and patients undergoing stem cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.